Yoshiaki Uyama

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2600836/publications.pdf

Version: 2024-02-01

10	109 citations	1937457 4 h-index	9 g-index
papers	citations	II-IIIQEX	g-index
10 all docs	10 docs citations	10 times ranked	63 citing authors

#	Article	IF	CITATIONS
1	Establishment of the MIDâ€NET [®] medical information database network as a reliable and valuable database for drug safety assessments in Japan. Pharmacoepidemiology and Drug Safety, 2019, 28, 1395-1404.	0.9	49
2	The utilization and challenges of Japan's MIDâ€NET [®] medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies. Pharmacoepidemiology and Drug Safety, 2019, 28, 601-608.	0.9	26
3	Cardiovascular risks associated with dipeptidyl peptidaseâ€4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study. Pharmacoepidemiology and Drug Safety, 2019, 28, 1166-1174.	0.9	8
4	Validity of identification algorithms combining diagnostic codes with other measures for acute ischemic stroke in <scp>MIDâ€NET®</scp> . Pharmacoepidemiology and Drug Safety, 2022, 31, 524-533.	0.9	6
5	Identification of gastrointestinal perforation based on ICDâ€10 code in a Japanese administrative medical information database and associated drug exposure risk factors. Pharmacoepidemiology and Drug Safety, 2019, 28, 976-984.	0.9	5
6	Effect of Hepatitis C Drugs on Blood Coagulability in Patients on Warfarin Using the Medical Information Database Network (MID-NETÄ®) in Japan. Therapeutic Innovation and Regulatory Science, 2021, 55, 539-544.	0.8	5
7	Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia. Therapeutic Innovation and Regulatory Science, 2022, 56, 523-529.	0.8	5
8	Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET® Medical Information Database Network in Japan. Therapeutic Innovation and Regulatory Science, 2022, 56, 625-631.	0.8	4
9	Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive Analysis. Therapeutic Innovation and Regulatory Science, 2021, 55, 1075-1081.	0.8	1
10	Characteristics on Drug Safety Measures in Japan Stratified by System Organ Classes and Therapeutic Categories in Relation to the Approval Date. Therapeutic Innovation and Regulatory Science, 2020, 54, 1534-1540.	0.8	0